Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis
about
Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-AnalysisCritical appraisal of bevacizumab in the treatment of ovarian cancerBevacizumab in ovarian cancer: A critical review of phase III studiesIs ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigationThe feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma.Effect of Avastin on the number and structure of tumor blood vessels of nude mice with A549 lung adenocarcinoma.Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth.Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysisEfficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future.Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.Improving outcomes for older women with gynaecological malignancies.Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients.The Role of Angiogenesis in Cancer Treatment.The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
P2860
Q26781561-7F8D0C3F-4CEC-4F30-B735-82429A028451Q26830403-96563FF6-90E3-44CB-8386-443ACBE06427Q28076188-5C00B9C0-1354-4638-84E5-AB2584238FD8Q31138109-D63A4395-2514-44CC-861F-828EDA49DC87Q33419382-1677203C-70EB-4963-9918-30868A9CF28EQ34443953-51E867C0-D749-42DA-B9B7-71F352EF5728Q34774917-8B7E1914-FF33-4D76-9013-79D4BBF464A2Q35039333-55D2DF57-0A8F-4A0B-8D14-6FEE5DBFB09EQ35920527-E4419576-8E92-41A9-9C8D-82BD8251CACDQ37022434-5FF1BC9E-233C-49C1-BB7C-E6595122F7D8Q38282823-C78DFFF9-C208-4A0A-BB22-CB839AD2EC2DQ38492121-32BAA36F-49FB-4259-8498-F4709FD2B262Q38963512-9CA2FA7D-7A39-4560-A196-52836DBB5E58Q47685928-DC9BDAED-92C8-49D2-8DC1-B57CF1539548Q50932310-6754CF73-5B27-4AE5-8E40-32DA751F3AB3Q54310257-69D925D2-87DB-414B-9408-76BF62A99544
P2860
Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase III trials of standard c ...... varian cancer: a meta-analysis
@ast
Phase III trials of standard c ...... varian cancer: a meta-analysis
@en
type
label
Phase III trials of standard c ...... varian cancer: a meta-analysis
@ast
Phase III trials of standard c ...... varian cancer: a meta-analysis
@en
prefLabel
Phase III trials of standard c ...... varian cancer: a meta-analysis
@ast
Phase III trials of standard c ...... varian cancer: a meta-analysis
@en
P2093
P2860
P921
P1433
P1476
Phase III trials of standard c ...... varian cancer: a meta-analysis
@en
P2093
Jingdong Zhang
Mingyi Zhou
Xiujuan Qu
Yunpeng Liu
P2860
P304
P356
10.1371/JOURNAL.PONE.0081858
P407
P577
2013-12-04T00:00:00Z